Anika Therapeutics, Inc. (ANIK)

Market Cap	197.06M -1.3%
Revenue (ttm)	116.26M -0.7%
Net Income	-11.06M
EPS	-0.78
Shares Out	13.31M
PE Ratio	n/a
Forward PE	65.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,890
Open	15.07
Previous Close	15.02
Day's Range	14.85 - 15.07
52-Week Range	7.87 - 16.24
Beta	0.16
Analysts	Buy
Price Target	17.50 (+18.16%)
Earnings Date	Apr 29, 2026

About ANIK

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Apr 29, 1993
• Employees: 235
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIK
• Website: https://www.anika.com

Financial Performance

In 2025, Anika Therapeutics's revenue was $112.82 million, a decrease of -5.91% compared to the previous year's $119.91 million. Losses were -$10.88 million, -80.70% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price target is $17.5, which is an increase of 18.16% from the latest price.

Price Target

$17.5

(18.16% upside)

Analyst Consensus: Buy